TRUSCREEN GROUP LIMITED — Capital/Financing Update 2026

May 20, 2026

ASX

Market Announcement

21 May 2026

TruScreen Group Limited (ASX: TRU) – Trading Halt

Trading in the securities of TruScreen Group Limited ('TRU') will be halted at the request of TRU, pending the release of an announcement by TRU.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

• the commencement of normal trading on Monday, 25 May 2026; or
• the release of the announcement to the market.

TRU's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

21 May 2026

ASX Limited

Market Announcement 1/1

ASX Customer Service Centre 131 279 | asx.com.au

---

truscreen®
a world without cervical cancer

NZX/ASX Announcement

21 May 2026

Trading Halt Request

To: ASX Limited
Level 27, 39 Martin Place
Sydney NSW 2000
Australia
TradingHaltsNZ@asx.com.au

NZ RegCo
11 Cable St
Wellington
New Zealand
issuer@nzregco.com

Request for Trading Halt: TruScreen Group Limited (NZX: TRU, ASX: TRU)

1. TruScreen Group Limited (TruScreen) requests a trading halt to be applied to its ordinary shares quoted on NZX and ASX (Shares) under NZX Listing Rule 9.9.1(a) and ASX Listing Rule 17.1, and set out below details of the request as per the rules of each of ASX and NZX.
2. TruScreen would like the trading halt to commence pre-market open on 21 May 2026 (being 8.30am NZT).

Reasons for Trading Halt

1. TruScreen proposes to undertake a capital raising, comprising of:

a. a placement to institutional and other select investors in New Zealand and Australia to raise up to NZ$1,000,000 (A$833,333) by the issue of up to 71,428,571 Shares at an issue price of NZ$0.014 (A$0.012) per Share (Placement) and one (1) Option for every two (2) New Shares subscribed with an exercise price of NZ$0.014 (A$0.012) and expiry date two (2) years from date of issue. TruScreen also intends to issue up to 30,000,000 options to the joint lead managers of the Placement (SP Corporate Advisory Pty Ltd and Erity Capital Pty Ltd) in consideration for services provided, subject to Shareholder approval; and
b. a one (1) for five (5) pro-rata renounceable rights issue to raise up to circa NZ$1.943 million (A$1.644 million) (Rights Offer).

1. TruScreen also proposes to offer a variation in respect of the 204,741,031 unlisted options currently on issue (the Existing Options) to extend the expiry date of all Existing Options to 17 July 2027. All other terms and conditions of the Existing Options, including the exercise price of NZ$0.022 (A$0.02) per option, will remain unchanged.

truscreen®
a world without cervical cancer

TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
c
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00 00 00 00 00 00 00

---

truscreen®
a world without cervical cancer

1. The amount of the Placement may be price sensitive for TruScreen's Shares and/or otherwise material for TruScreen.

How long we want the Trading Halt to last

1. Accordingly, TruScreen requests a halt in the trading of TruScreen's Shares from pre-market open on 21 May 2026 (being 8.30am NZT), with trading resuming at the earlier of:
   a. market open on 25 May 2026 in respect of the NZX and ASX; or
   b. the time of the announcement that the Placement has completed.

2. TruScreen expects to be able to make an announcement to the market via the NZX Market Announcement Platform and on the ASX that the Placement has completed no later than 10.00am NZT on 25 May 2026 (the Placement Completion Announcement).

3. As soon as the trading halt is applied, TruScreen expects to be in a position to announce to the market via the NZX Market Announcement Platform and on ASX that the Placement is occurring (including an NZX cleansing notice and investor presentation) and is proposed to be followed by the Rights Offer. The halt should continue to apply despite these announcements being made - it is only the Placement Completion Announcement that should lift the trading halt. TruScreen will confirm with you at the time the Placement Completion Announcement is made that the halt should be lifted.

The event we expect to happen that will end the Trading Halt

1. We expect the trading halt to end on the issue, by TruScreen, of the Placement Completion Announcement.

2. TruScreen confirms it has no other information necessary to inform the market about the trading halt or that ASX or NZ RegCo have requested and that it is not aware of any reason why the trading halt should not be granted.

3. TruScreen will advise you upon becoming aware if the Placement Completion Announcement referred to above will not be made or if there is to be a change in timeframe.

4. Please contact TruScreen if you require further information in relation to the above

Approved by the TruScreen Group Limited Board.

Yours sincerely

For and on behalf of TruScreen Group Limited

Guy Robertson

truscreen
a world without cervical cancer

TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00 00 00 00 00 00 00

---

truscreen®
a world without cervical cancer

Chief Financial Officer
Truscreen Group Limited

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Jack Zhang
Media & Investor Relations
jack@sparkplus.org

truscreen®
a world without cervical cancer

TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00 00 00 00 00 00

---

truscreen®
a world without cervical cancer
^{}[]

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”.

To learn more, please visit: www.truscreen.com/.

*Based on Single Use Sensor sales.

^{}[]
truscreen
a world without cervical cancer
TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 13485
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00
^{}[]

---

truscreen®
a world without cervical cancer
^{}[]

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening. DALTONbio’s exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.

^{}[]
truscreen®
a world without cervical cancer
TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
国际药品监督管理局